Skip to main content


Table 5 Multivariate stepwise regression analyses of data from 147 patients with axial spondyloarthritis followed over 2 years assessing the associations between treatment and development of erosion or fat metaplasia

From: Tumor necrosis factor inhibitor therapy but not standard therapy is associated with resolution of erosion in the sacroiliac joints of patients with axial spondyloarthritis

  β coefficient SE t value P value
2 year change in ASDAS −0.43 0.15 −2.83 0.006
2 year change in SPARCC SIJ inflammation score −0.077 0.032 −2.40 0.019
Baseline SSS score for fat metaplasia 0.085 0.039 2.16 0.034
  1. Dependent variable: 2-year change in SSS for fat metaplasia. Adjusted R2 = 0.18. Variables not included in the model: age, sex, symptom duration, treatment, baseline ASDAS, baseline and 2-year change in C-reactive protein, baseline SPARCC SIJ inflammation score, baseline SSS for backfill, and baseline SSS for erosion. ASDAS, Ankylosing Spondylitis Disease Activity Score; SE, standard error; SIJ, sacroiliac joint; SPARCC, Spondyloarthritis Research Consortium of Canada; SSS, sacroiliac joint structural score.